Abstract 2273 Developing Engineered STING-ICG Lipid Nanoparticles (LNPs) for Trackable Delivery in BRCA-Deficient Breast Cancer Treatment

Breast cancer is the most common cancer affecting females in the United States with estimated 300,000 people diagnosed each year. Over 60% of women with mutations in the BReast CAncer (BRCA) gene are more prone to developing breast cancer in their lifetime compared to 13% of the general population. Poly ADP Ribose Polymerase inhibitors (PARPi), which are small-molecule drugs, have played a crucial role in inhibiting the DNA repair of BRCA – deficient breast cancer cells to prevent their growth and proliferation.